Lexaria Bioscience Corp Stock Price, News & Analysis

Lexaria Bioscience (NASDAQ:LEXX) closed a registered direct offering of 2,661,600 common shares at $1.315 per share and concurrently issued unregistered warrants to purchase up to 2,661,600 shares.

The warrants carry a $1.19 exercise price, are immediately exercisable and expire five years after the resale registration statement became effective. Aggregate gross proceeds were approximately $3.5 million, before placement agent fees and expenses. H.C. Wainwright acted as exclusive placement agent. Net proceeds are intended for R&D, working capital and general corporate purposes.

Lexaria Bioscience (NASDAQ:LEXX) announced a registered direct offering of 2,661,600 shares of common stock at $1.315 per share, with aggregate gross proceeds expected to be approximately $3.5 million before fees and expenses. The offering is priced at-the-market under Nasdaq rules and is expected to close on or about December 16, 2025, subject to customary conditions.

In a concurrent private placement the company will issue unregistered warrants to purchase up to 2,661,600 shares at an exercise price of $1.19 per share; the warrants are immediately exercisable and expire five years after effectiveness of the resale registration statement. H.C. Wainwright & Co. is sole placement agent. Net proceeds are intended for R&D, working capital and general corporate purposes.

Lexaria Bioscience (NASDAQ:LEXX, LEXXW) entered a definitive agreement for a registered direct offering of 2,666,667 common shares at $1.50 per share and a concurrent private placement of unregistered warrants to purchase up to 2,666,667 shares.

The warrants carry a $1.37 exercise price, are immediately exercisable and expire five years from the effectiveness of the resale registration statement. Aggregate gross proceeds are expected to be approximately $4.0 million before placement agent fees and expenses. The closing is expected on or about September 29, 2025, subject to customary conditions.

Proceeds are intended for working capital and general corporate purposes; the registered shares are offered under an effective Form S-3 shelf registration.

Lexaria (Nasdaq:LEXX) announced an extension to its Material Transfer Agreement with a pharmaceutical company through April 30, 2026 to allow PharmaCO time to receive and review the full dataset from Lexaria's Australian human study GLP-1-H24-4.

The extension keeps the temporary exclusive license active and preserves the parties' ability to continue strategic planning with PharmaCO's human clinical development team. Lexaria said initial pre-clinical pharmacokinetic animal studies under the MTA were completed earlier in 2025 and that final results from the Australian study are projected to be released before the end of Q4 2025.

Lexaria Bioscience (NASDAQ:LEXX) announced strategic updates including engagement of a global life‑science business development advisory firm, completion of an equity financing raising $4.0 million gross, and award of 4 new patents covering diabetes, epilepsy, antiviral delivery and infused food/beverage applications (grant dates Jul–Oct 2025).

The funding extends operations beyond 2025, supports expanded R&D into 2026, and enables increased outreach to pharmaceutical and biotech partners. Final results from a Phase 1b Australian GLP‑1 study are anticipated and further R&D budget decisions will be announced later.

Lexaria Bioscience (NASDAQ:LEXX) has successfully closed a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The offering consisted of 2,666,667 shares of common stock at $1.50 per share.

Additionally, the company issued unregistered warrants in a concurrent private placement to purchase up to 2,666,667 shares of common stock with an exercise price of $1.37 per share. These warrants are immediately exercisable and have a five-year expiration term.

H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes, with a focus on supporting their 2026 R&D and business development initiatives.

Lexaria Bioscience (NASDAQ:LEXX), a global drug delivery platform innovator, has announced a $4.0 million registered direct offering priced at-the-market under Nasdaq rules. The company will sell 2,666,667 shares of common stock at $1.50 per share.

Additionally, in a concurrent private placement, Lexaria will issue unregistered warrants to purchase up to 2,666,667 shares with an exercise price of $1.37 per share. The warrants will be immediately exercisable and expire in five years. H.C. Wainwright & Co. serves as the exclusive placement agent, with the offering expected to close around September 29, 2025.

Lexaria Bioscience (Nasdaq:LEXX) has announced positive results from its fluorescently tagged semaglutide (FTS) rodent biodistribution study, demonstrating that its DehydraTECH technology enhances brain delivery of the GLP-1 drug semaglutide.

The study revealed that DehydraTECH-FTS showed higher brain biodistribution compared to Rybelsus® equivalent composition, with the 5mg DehydraTECH-FTS achieving higher brain semaglutide fluorescent signal intensity than the 15mg Rybelsus® equivalent. The enhanced brain delivery could potentially improve both safety and efficacy of GLP-1 drugs, particularly in areas related to appetite suppression and nausea reduction.

These findings suggest that Lexaria's technology may enable unique delivery enhancements in brain tissue, potentially supporting improved pharmacodynamic performance of GLP-1 drugs.

Lexaria Bioscience (NASDAQ:LEXX), a global innovator in drug delivery platforms, announced its participation in the upcoming 27th Annual H.C. Wainwright Global Investment Conference from September 8-10th, 2025.

CEO Richard Christopher will deliver a company presentation, which will be available for remote viewing starting September 5th at 7:00 AM EST. The management team will also be available for one-on-one meetings with investors throughout the conference.